Pacira BioSciences announces pricing of convertible senior notes due 2029 [Seeking Alpha]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Seeking Alpha
Pacira ( PCRX ) also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on May 14. Pacira estimates that the net proceeds from the offering will be approximately $242.0 million. The notes will be general unsecured senior obligations of Pacira and will mature on May 15, 2029, unless earlier repurchased, redeemed or converted in accordance with their terms. The notes will bear interest at a fixed rate of 2.125% per year, payable semi- annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2024. The conversion rate will initially be 25.2752 shares of common stock per $1,000 principal amount of notes, subject to adjustment in certain circumstances. This represents an initial conversion price o
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029GlobeNewswire
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesGlobeNewswire
- Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
PCRX
Earnings
- 5/7/24 - Beat
PCRX
Sec Filings
- 5/14/24 - Form 8-K
- 5/8/24 - Form 8-K
- 5/7/24 - Form 10-Q
- PCRX's page on the SEC website